reports
Net Asset Value(s)
Net Asset Value(s) WisdomTree Issuer plc – Daily Fund Prices 04-April-25 WisdomTree Artificial Intelligence UCITS ETF - USD Acc04/04/2025IE00BDVPNG1311666630USD603,203,428.6951.7033WisdomTree AT1 CoCo Bond UCITS ETF - EUR Hedged04/04/2025IE00BFNNN2362642473EUR218,182,643.9182.5676WisdomTree AT1 CoCo Bond UCITS ETF - GBP Hedged04/04/2025IE00BFNNN459104059GBP9,127,517.9987.7148WisdomTree AT1 CoCo Bond UCITS ETF - USD04/04/2025IE00BZ0XVF52750537USD63,615,350.1084.7598WisdomTree AT1 CoCo Bond UCITS ETF - USD Acc04/04/2025IE00BZ0XVG6966530USD8,247,851.83123.9719WisdomTree...
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 ...
Issuer: CureVac / Key word(s): Study/Regulatory Approval CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer 07.04.2025 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac’s investigation...
EQS-News: CureVac erhält IND-Freigabe der U.S.-amerikanischen FDA für ...
Emittent / Herausgeber: CureVac / Schlagwort(e): Studie/Zulassungsgenehmigung CureVac erhält IND-Freigabe der U.S.-amerikanischen FDA für den Start einer klinischen Phase 1-Studie mit einer neuartigen mRNA-Präzisions-Immuntherapie beim Plattenepithelkarzinom der Lunge 07.04.2025 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac erhält IND-Freigabe der U.S.-amerikanischen FDA für den Start einer klinischen Phase 1-Studie mit einer neuartigen mRNA-Präzisions-Immuntherapie beim Plattenepithelkarzinom der Lunge Bedeutende...
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Offic...
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant ...
Kraig Biocraft Laboratories is Happy to Announce its New Director of M...
Kraig Biocraft Laboratories is Happy to Announce its New Director of Molecular Biology as it Accelerates Advanced Fibers Development ANN ARBOR, Mich., April 07, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk-based super materials, is pleased to announce the appointment of Dr. Xiaoli Zhang as Director of Molecular Biology. Dr. Zhang is a proven research and development leader in the field of molecular biology and bioengineering, with numerous groundbreaking accomplishments in spider silk and transgenic ...
Gilat Awarded Up to $23 Million Multi-Year Contract to Service Satelli...
Gilat Awarded Up to $23 Million Multi-Year Contract to Service Satellite Transportable Terminal Units for US DoD Customers Gilat Defense will ensure the operational readiness of critical SATCOM systems worldwide PETAH TIKVA, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that Gilat Defense was awarded a contract to provide ongoing sustainment and support services for Satellite Transportable Terminal (STT) units deployed worldwide in support...
Indkaldelse til ordinær generalforsamling 2025 i NewCap Holding A/S
Indkaldelse til ordinær generalforsamling 2025 i NewCap Holding A/S Selskabsmeddelelse nr. 3 / 2025 7. april 2025 Indkaldelse til ordinær generalforsamling 2025 i NewCap Holding A/S Den ordinære generalforsamling i NewCap Holding A/S afholdes tirsdag den 29. april 2025, kl. 09:30 på adressen Oslo Plads 2, 2100 København Ø. Generalforsamlingen afholdes som en fysisk generalforsamling. Aktionærerne har mulighed for at følge – men ikke deltage i - generalforsamlingen via livestreaming. Aktionærer, der ønsker at følge generalforsamlingen via livestream, opfordres til at stemme forud for gen...
Scope Metals Group Ltd: 1 director
A director at Scope Metals Group Ltd bought 8,500 shares at 119.613ILS and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
AU Small Finance Bank Limited: 1 director
A director at AU Small Finance Bank Limited bought 22,544 shares at 534.150INR and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
Signify share repurchase period update
Signify share repurchase period update Press ReleaseApril 07, 2025Signify share repurchase period update Eindhoven, the Netherlands – (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 131,068 shares in the period March 31 to April 04, 2025. The shares were repurchased at an average price of EUR 19.22 per share and an aggregate amount of EUR 2.5 million. Signify will use these repurchased shares to cover obligations arising from Signify’s long-term incentive performance share plan and other employee share plans.The repurchases were made as part of the ...
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatm...
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibr...
Shoals Technologies Group, Inc. Announces First Quarter 2025 Earnings ...
Shoals Technologies Group, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call PORTLAND, Tenn., April 07, 2025 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its first quarter 2025 results before market open on Tuesday, May 6, 2025, to be followed by a conference call at 8:00 a.m. (Eastern Time) on the same day. Interested investors and other parties can access the live webcast through the Investor Relations section of the Company's website at . An archived replay of the webcast will...
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth ...
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA Award for the fourth consecutive year. The national award program by Energage and USA Today celebrates organizations with 150 or more employees that have built exceptional workplace cultures. Castle was ranked 30th among 358 participating U.S. companies with 500-999 employees....
Atwater Brewery Releases Atwater Light: Detroit’s Premium Light Craft ...
Atwater Brewery Releases Atwater Light: Detroit’s Premium Light Craft Beer Atwater Light Brings a Crafted Touch to Low-Calorie beer, Inspired by the Spirit of Detroit DETROIT, April 07, 2025 (GLOBE NEWSWIRE) -- , Detroit’s renowned craft brewery and a craft beer brand of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is pleased to announce the launch of Atwater Light, a low-calorie, low-carb addition to its flagship line available year-round. This new product is now offered at local retailers and all three Atwater Tap Rooms and is anticipated to become a preferred choice for beer ent...
Plymouth Industrial REIT Provides Activity Update for First Quarter 20...
Plymouth Industrial REIT Provides Activity Update for First Quarter 2025 Announces Details for First Quarter Earnings Conference Call BOSTON, April 07, 2025 (GLOBE NEWSWIRE) -- (NYSE: PLYM) (the “Company” or “Plymouth”) provided an activity update for the first quarter of 2025. The Company also announced details for its first quarter earnings conference call and webcast to be held on May 2, 2025. Jeff Witherell, Chief Executive Officer and Co-Founder of Plymouth, noted, “Our strong leasing activity in the first quarter underscores the continued demand for well-located, functional indu...
Standard Uranium Executes Letter of Intent to Option Corvo Project in ...
Vancouver, British Columbia--(Newsfile Corp. - April 7, 2025) - Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce that it has signed a letter of intent (the "LOI"), dated April 4, 2025, with Vital Battery Metals Inc. (CSE: VBAM) (OTCQB: VBAMF) (FSE: C0O) (the "Optionee"), an arms-length party. Pursuant to the LOI, the Optionee will be granted the option (the "Option") to acquire a seventy-five percent interest in the 12,265-hectare Corvo Project ("Corvo" or the "Project") located in the eastern Athabasca Basin region (Fi...
ADMA Biologics Statement on Tariffs
ADMA Biologics Statement on Tariffs Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA’s strategic advantage through fully U.S.-base...
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets...
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity -- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p
Update on Extraordinary General Meeting – Extension of Zijin Put Optio...
Update on Extraordinary General Meeting – Extension of Zijin Put Option and Exclusivity Arrangements TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) refers to its announcement dated 12 March 2025 in relation to an Extraordinary General Meeting (EGM) to be held on Friday, 11 April 2025. The EGM included a resolution to approve the exercise of a put option previously granted by the Company’s major shareholder and joint venture partner, Zijin Mining Group Co. Ltd (Zijin), to allow the Company to dispose of a 25% interest in Khu...
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results ...
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Orphan medicinal product designation granted to deucrictibant in Europe for the treatment of bradykinin-mediated angioedemaData presented at recent congresses reinforces the value of deucri...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.